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ABSTRACT
Objectives: To evaluate the effects of a combined Myo-inositol (MI) and D-chiro-inositol (DCI) therapy on the hormonal and 
metabolic parameters of women with PCOS. Prospective clinical study. Clinical Study registration number — EUPAS25705
Material and methods: Seventy women diagnosed with PCOS according to the Rotterdam criteria were enrolled in 
this study. Patients received a combined therapy of one tablet that contained 550 mg of inositol (myo-inositol (MI) and 
D-chiro-inositol (DCI) in a ratio of 10:1) twice a day for 6 months. At each of 3 visits, the body weight, height and BMI were 
all recorded; and serum levels of free testosterone (fT), sex hormone-binding globulin (SHBG), luteinizing hormone (LH), 
follicle-stimulating hormone (FSH) and glucose with insulin during standard OGTT (75 g) were measured. Also at each visit, 
transvaginal ultrasonography and skin condition assessments were performed.
Results: Significant body weight reduction and decreases in fT, FSH, LH and insulin levels, as well as significant increase 
of serum SHBG concentrations were observed. Serum glucose levels during OGTT decreased after 6 months of treatment. 
Also, skin conditions improved after only three months of treatment.
Conclusions: Combination of MI and DCI in a ratio 10:1 seems to be efficient in improving both metabolic and hormonal 
parameters in patients with PCOS. 
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is one of the most 
common endocrinopathies in women of reproductive age, 
with a prevalence of 4–18% [1]. According to the 2003 Rot-
terdam criteria, diagnosis of PCOS is made when 2 out of 
3 features are present: oligo- and/or anovulation, clinical 
and/or biochemical signs of hyperandrogenism, and/or 
ultrasonographic findings of polycystic ovaries; and any 
other etiologies of hyperandrogenism are excluded. PCOS 
typically presents with irregular menstrual cycles, infertility, 
and clinical signs of hyperandrogenism, including hirsutism, 
acne and androgenic alopecia [2–4].
Increasing evidence supports the important role played 
by insulin resistance and compensatory hyperinsulinemia, 
that are commonly observed in these patients, both obese 
and lean [5–7]. It was hypothesized that in patients with 
PCOS, insulin resistance and compensatory hyperinsuline-
mia stimulates the secretion of both ovarian and adrenal 
androgen, and they suppress hepatic synthesis of the sex 
hormone binding globulin (SHBG). This leads to hyperan-
drogenism and subsequent premature follicular atresia 
and anovulation as well as leading to gonadotropin im-
balance (an increase in LH and a decrease in FSH), which 
are characteristic of PCOS [8, 9]. This insulin resistance also 
determines an increased risk of cardiometabolic disorders 
such as obesity, impaired glucose tolerance, type 2 diabetes 
(DM2), dyslipidemia, hypertension, metabolic syndrome and 
cardiovascular disease [10, 11].
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The important roles of insulin resistance and hyperinsu-
linemia in the pathogenesis of PCOS are confirmed by the 
favorable response of PCOS patients to insulin-sensitizing 
drugs, with improved ovulatory function and reduced cir-
culating androgens [12].
Insulin resistance is hypothesized to be related to al-
tered insulin signaling, probably due to a defect in the inosi-
tolphosphoglycan (IPG) second messenger pathway [13–15].
The cellular content of INS is represented almost entirely 
by MI (> 99%) and for the remaining part by D-chiro-inositol 
(DCI) [16].
The aim of the present study was to evaluate the ef-
fect of a combined MI + DCI therapy on the metabolic and 
hormonal parameters in PCOS patients.
MATERIAL AND METHODS
Subjects and study design
A group of 70 women who had been diagnosed with PCOS 
according to the Rotterdam criteria were enrolled in our pro-
spective clinical study. The patients were enrolled from January 
2015 to December 2016. Informed consent was obtained from 
all patients. The study was approved by the Bioethical Commit-
tee of the Central Clinical Hospital of the Interior in Warsaw. The 
gynecological history of each woman was obtained. The patients 
were asked about their attempts at conception, their history of 
oligoovulation or anovulation, acne and hirsutism; in addition we 
collected ultrasonographic findings of a polycystic ovary exami-
nation that we conducted with each patient on their first visit. 
The patients received for 6 months, from the first visit, 
1100 mg of inositol in two tablets daily (a combination of 
Myo-inositol and D-chiro-inositol in a ratio 10:1, with a daily 
dose of: 400 μg of folic acid, 1000 IU of vitamin D, 1.4 mg of 
vitamin B6, 6 mg of vitamin B5, and 2.5 μg of vitamin B12). 
The patients were followed up at 3 and 6 months from the 
date of their first visit. At each visit (v1 – before treatment, 
v2 – 3 months after initiation of treatment, v3 – 6 months 
after initiation of treatment), anthropometric measurements 
including weight, height and body mass index (BMI) were 
recorded. Plasma concentrations of free testosterone (fT), 
sex hormone-binding globulin (SHBG), luteinizing hormone 
(LH), follicle-stimulating hormone (FSH), fasting glucose and 
fasting insulin were assessed. An oral glucose tolerance test 
(OGTT) with 75 g of glucose was performed; and plasma 
glucose concentration, before oral glucose load, 1 h after, and 
2 h after, was measured. Skin condition assessment, using the 
Acne Global Severity Scale, was performed. At each follow-up 
visit, the patients’ compliance regarding the prescribed treat-
ment and recommended lifestyle modifications was checked.
Statistical analysis
Quantitative data are presented as mean±SD. The Wil-
coxon test was used to determine whether the differences 
(both between the first and second visits, and between the 
first and third visits) were statistically significant and a Bon-
ferroni correction was applied for multiple comparisons. The 
significance level was set at 0.05/2 = 0.025. The percentage 
distribution was presented for qualitive data, such as skin 
condition, at the second and the third visits in relation to 
the first visit. To determine whether the data distribution 
differences were statistically significant, the Χ2 test was 
used and when the expected frequency in any cell was less 
than 5, the Fisher’s Exact Test was applied. The significance 
level was set at α = 0.05. 
RESULTS
A significant reduction of body weight, fT, FSH, LH and 
insulin plasma concentration, as well as a significant increase 
of the SHBG plasma concentration were observed at both 
the second and third visits when compared with the first 
visit; i.e. before administration of treatment (in all cases 
p < 0.001). Moreover, statistically significant differences in 
the OGTT results were observed between the first and sec-
ond visits, as well as between the first and third visits. The 
results are summarized in Table 1. Statistically significant 
differences were also observed between the second and 
third visits in regard to skin condition (p < 0.004).
DISCUSSION
Inositol is involved in a great variety of functions, in-
cluding cell membrane formation, cell growth and survival 
(morphogenesis, cytoskeleton rearrangement, regulation of 
cell proliferation), and in intracellular signaling, the develop-
ment and function of peripheral nerves, osteogenesis and 
reproduction [17–20].
The present study found that a combined MI + DCI ther-
apy in a ratio of 10:1 significantly improved the metabolic 
and hormonal parameters in PCOS patients. In our opinion, 
this is the first paper in the literature which is focused on 
the metabolic and hormonal changes in patients with PCOS 
following a combined MI + DCI therapy in this 10:1 ratio. 
Significant decreases in body weight, fT, FSH, LH and insu-
lin plasma concentration, as well as a significant increase 
in SHBG plasma concentration, were observed both after 
3 months and after 6 months of MI + DCI treatment in a ratio 
of 10:1 (Tab. 1). Statistically significant differences were also 
observed regarding patients’ skin condition.
Artini et al. [8] evaluated the effects of the administration 
of MI on hormonal parameters in a group of 50 overweight 
women with PCOS and reported that after 12 weeks of 
treatment, plasma LH, PRL, T, insulin levels and LH/FSH were 
significantly reduced; also that the insulin sensitivity signifi-
cantly improved, and the menstrual cyclicity was restored 
in all amenorrheic and oligomenorrheic subjects. Similarly, 
Genazzani et al. [21] reported that after 12 weeks of MI 
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administration, plasma LH, PRL, T, insulin levels and LH/FSH 
were significantly reduced and that insulin sensitivity sig-
nificantly improved, in a study carried out on 20 overweight 
women with PCOS. Moreover, menstrual cyclicity was also 
restored in all amenorrheic and oligomenorrheic subjects. 
In another study, the efficacy of 8 weeks of treatment with 
MI at the dosage of 2 g per day, on the insulin sensitivity 
and hormonal parameters in a group of obese patients 
with PCOS was investigated. After the treatment interval, 
the patients’ body mass index (BMI) and insulin resistance 
decreased together with LH, LH/FSH and insulin [22].
Another stereoisomer of INS, i.e. DCI, was evaluated in 
a study by Nestler et al. [23], in which the authors found that 
the administration of D-chiro-inositol to obese women with 
PCOS decreased the insulin response to orally administered 
glucose (most likely due to an improvement in peripheral 
insulin sensitivity), and improved ovulatory function and 
several metabolic abnormalities related to insulin resistance, 
such as serum androgen concentrations, blood pressure, 
and plasma triglyceride [24].
Nordio and Proietti [25], in a study of overweight wom-
en with PCOS, compared the effectiveness of a combined 
MI + DCI therapy in a physiological plasma ratio (40:1) 
with a monotherapy with MI, in reducing the risk of meta-
bolic syndrome as well as in enhancing the ovarian func-
tions. In that study, both MI and MI+DCI groups showed 
an improvement in the metabolic parameters and no sig-
nificant differences between the groups were observed 
after six months of treatment. However, it was found that 
a combined therapy was able to restore the hormonal and 
metabolic parameters earlier than when the patients were 
treated with MI alone, with significant changes evident in 
the metabolic profile between the MI and MI + DCI groups 
after three months of treatment. The researchers therefore 
speculated that DCI rapidly reduces the peripheral hyper-
insulinemia while the presence of MI mainly improves the 
ovulatory function. They concluded that the combined 
administration of MI and DCI in a physiological plasma ratio 
(40:1) should be considered as the first line of approach in 
overweight patients with PCOS, thus reducing the meta-
bolic and clinical alteration of PCOS and, therefore, also 
reducing the risk of metabolic syndrome. Results consist-
ent with these above were reported by Benelli et al. [9] in 
a study of obese women with PCOS, in which the authors 
found the therapeutic combination of MI + DCI (in a ratio 
of 40:1) to improve the endocrine proﬁle and the insulin 
resistance compared with the placebo (folic acid). In that 
study, the authors also recorded a statistically signiﬁcant 
reduction of LH, fT, fasting insulin, and the HOMA index; 
and a statistically signiﬁcant increase of 17-beta-Estradiol 
and SHBG levels.
In the present study, significant improvements in meta-
bolic and hormonal parameters were also observed after 
only three months of treatment. Moreover, Colazingari et 
al. [26] investigated the effects on oocyte quality of the 
combined treatment of MI + DCI (in a ratio of 40:1) versus 
a DCI monotherapy, and found that only the combined 
therapy was able to improve oocyte and embryo quality, 
as well as pregnancy rates, in women with PCOS who were 
undergoing IVF-ET. Similarly, Brusco et al. [27] showed that 
MI + DCI in the lower, 5:1 ratio significantly improved the 
overall quality of oocytes and consequently embryo devel-
opment. As was mentioned earlier, ours is the first report 
in the literature that is focused on the metabolic and hormo-
nal parameters of a combined MI + DCI therapy in patients 
with PCOS, where the ratio of stereoisomers is 10:1.
Table 1. Quantitative data obtained at the first, second and third visits and the Wilcoxon test results (significance level set at p < 0.025)
First visit Mean ± SD Second visit Mean ± SD Third visit Mean ± SD p-value v1 vs. v2
p-value 
v1 vs. v3
Age 28.4 ± 5.1
Height [cm] 165.2 ± 12.2
Weight [kg] 79.2 ± 17.0 75.2 ± 14.7 72.3 ± 12.3 < 0.001 < 0.001
Free testosterone [pg/mL] 4.2 ± 2.4 3.6 ± 1.6 3.3 ± 1.3 < 0.001 < 0.001
SHBG [nmol/L] 44.1 ± 34.0 46.1 ± 29.8 48.0 ± 27.8 < 0.001 < 0.001
FSH [mIU/mL] 8.1 ± 3.1 7.2 ± 2.4 6.9 ± 2.0 < 0.001 < 0.001
LH [mIU/mL] 12.4 ± 6.7 10.8 ± 5.5 9.3 ± 4.2 < 0.001 < 0.001
Glucose-0’ OGTT [mmol/L] 6.4 ± 10.7 9.3 ± 18.5 5.8 ± 8.0 0.004 < 0.001
Glucose-
1-h OGTT [mmol/L] 7.5 ± 1.5 7.2 ± 1.5 7.1 ± 1.6 0.009 0.006
Glucose-
2-h OGTT [mmol/L] 6.4 ± 1.3 7.7 ± 11.7 7.3 ± 10.9 < 0.001 < 0.001
Fasting insulin [μIU/mL] 13.0 ± 6.4 11.5 ± 5.3 10.2 ± 4.2 < 0.001 < 0.001
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CONCLUSIONS
In conclusion, a combined MI + DCI treatment (in a ratio 
of 10:1) seems to be efficient in improving both metabolic 
and hormonal parameters and skin conditions in patients 
with PCOS.
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